AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., July 20, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced the strengthening of its leadership team with the appointments of Mr. Robert Williamson as President, Chief Operating Officer and member of the Board of Directors, Mr. Jeffrey Erickson as VP of Business Development, and Mr. Chris Murray as VP of Human Resources.
“The appointment of Robert as our President and Director, Chris as our VP of Human Resources, and the addition of Jeffrey to the team will be instrumental in our efforts to expand our team of experts and advance our T cell Antigen Coupler (TAC) technology and lead assets, including our novel autologous cell therapy TAC100-HER2, to late-stage clinical development,” said Paul Lammers, M.D., M.Sc., Chief Executive Officer of Triumvira. “We couldn’t be more excited to bring them on board.”
